Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateTimeSourceHeadlineSymbolCompany
26/06/202405:30GlobeNewswire Inc.Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery PlatformNASDAQ:NTLAIntellia Therapeutics Inc
17/06/202421:30GlobeNewswire Inc.Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024NASDAQ:NTLAIntellia Therapeutics Inc
15/06/202406:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
15/06/202406:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
15/06/202406:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
15/06/202406:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
14/06/202421:30GlobeNewswire Inc.Intellia Therapeutics Names Brian Goff to its Board of DirectorsNASDAQ:NTLAIntellia Therapeutics Inc
14/06/202406:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
02/06/202422:00GlobeNewswire Inc.Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
10/05/202406:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NTLAIntellia Therapeutics Inc
09/05/202421:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
09/05/202421:30GlobeNewswire Inc.Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
02/05/202421:30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
29/04/202421:30GlobeNewswire Inc.Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024NASDAQ:NTLAIntellia Therapeutics Inc
18/03/202422:30GlobeNewswire Inc.Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with CardiomyopathyNASDAQ:NTLAIntellia Therapeutics Inc
06/03/202408:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
06/03/202408:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
06/03/202408:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
06/03/202408:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
06/03/202408:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
26/02/202423:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NTLAIntellia Therapeutics Inc
24/02/202409:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
23/02/202408:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NTLAIntellia Therapeutics Inc
23/02/202408:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NTLAIntellia Therapeutics Inc
22/02/202423:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
22/02/202423:30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
15/02/202423:30GlobeNewswire Inc.Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic FibrosisNASDAQ:NTLAIntellia Therapeutics Inc
15/02/202423:30Business WireIntellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic FibrosisNASDAQ:NTLAIntellia Therapeutics Inc
14/02/202423:30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
02/02/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA